...
首页> 外文期刊>Protein Expression and Purification >Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris
【24h】

Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris

机译:巴斯德毕赤酵母中表达的人乳头瘤病毒58病毒样颗粒的纯化和免疫原性研究

获取原文
获取原文并翻译 | 示例

摘要

Two human papillomavirus (HPV) prophylactic vaccines are currently available in the market: Gardasil and Cervarix. These two vaccines work against tumor high-risk subtypes HPV 16 and HPV 18. However, they do not include other high-risk subtypes such as HPV 58. Epidemiological research in China shows that HPV 58 is a prevalent high-risk subtype, second only to HPV 16 and HPV 18. Thus, for cervical cancer prevention in China, developing a vaccine against HPV 58 is necessary. In this study, HPV 58 virus-like particles (VLPs) were expressed in the Pichia pastoris, and subsequently purified through pretreatment and a three-step purification process consisting of strong cation exchange chromatography, size-exclusion chromatography, and hydroxyapatite chromatography. The highly purified HPV 58 VLPs were confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, electron microscopy, dynamic laser scattering, and ultracentrifugation. The purified VLPs were used to immunize mice to test their ability to induce humoral immunity. Enzyme-linked immunosorbent assays were performed on the sera of the immunized mice and significantly high anti-HPV 58 VLP antibody titers were observed. The immunogenicity study demonstrates that the purified HPV 58 VLPs are HPV vaccine candidates.
机译:目前市场上有两种人乳头瘤病毒(HPV)预防性疫苗:Gardasil和Cervarix。这两种疫苗可对抗肿瘤高危亚型HPV 16和HPV18。但是,它们不包括其他高危亚型,例如HPV58。中国的流行病学研究表明,HPV 58是流行的高危亚型,仅次于HPV 16和HPV18。因此,为了在中国预防子宫颈癌,必须开发针对HPV 58的疫苗。在这项研究中,HPV 58病毒样颗粒(VLP)在巴斯德毕赤酵母中表达,随后通过预处理和由强阳离子交换色谱,尺寸排阻色谱和羟基磷灰石色谱组成的三步纯化过程进行纯化。十二烷基硫酸钠聚丙烯酰胺凝胶电泳,电子显微镜,动态激光散射和超速离心证实了高纯度的HPV 58 VLP。纯化的VLP用于免疫小鼠以测试其诱导体液免疫的能力。在免疫小鼠的血清上进行酶联免疫吸附测定,观察​​到明显高的抗HPV 58 VLP抗体滴度。免疫原性研究表明,纯化的HPV 58 VLP是候选HPV疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号